血清Vaspin Endocan在不稳定型心绞痛合并高血压病的表达及其临床意义

doi:10.3969/j.issn.1006-6233.2019.02.019

摘要
图/表
参考文献
相关文章 (2)

全文: PDF (1570 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的:探讨脂肪特异性丝氨酸蛋白酶抑制剂(Vaspin)、内皮细胞特异分子-1(Endocan)在不稳定型心绞痛合并高血压病中的表达及临床意义。方法:收集2017年2月至2018年2月在我院住院的高血压病患者43例为高血压病组,不稳定型心绞痛患者61例为UA组,不稳定型心绞痛合并高血压病患者90例为UA合并高血压病组,正常人35例为对照组,采用酶联免疫吸附试验(ELISA)检测所有入选患者Vaspin、Endocan水平,并进行统计学分析。结果:Vaspin和Endocan水平在高血压病组、UA组及UA合并高血压病组较对照组差异均有统计学意义(P<0.05),且Vaspin水平在高血压病组、UA组及UA合并高血压病组逐渐下降,Endocan水平在高血压病组、UA组及UA合并高血压病组逐渐升高,差异均有统计学意义(P<0.05)。UA组和UA合并高血压病组Vaspin水平与冠脉病变支数及冠脉Gensini评分呈负相关(P<0.05),Endocan水平与冠脉病变支数及冠脉Gensini评分呈正相关(P<0.05),Vaspin与Endocan两指标呈显著负相关(r=-0.715,P<0.05)。ROC曲线分析显示,以高血压病组为参考时,血清Vaspin、Endocan诊断UA合并高血压病的曲线下面积分别为0.877、0.850(P<0.05),以UA组为参考时,血清Vaspin、Endocan诊断UA合并高血压病的曲线下面积分别为0.692、0.689(P<0.05)。结论:血清Vaspin和Endocan水平在UA合并高血压病患者中可作为早期诊断及评估病情的客观指标。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：脂肪特异性丝氨酸蛋白酶抑制剂, 内皮细胞特异分子-1, 不稳定型心绞痛, 高血压病

Abstract：Objective: To investigate the expression and clinical meaning of visceral adipose tissue-derived serine protease inhibitor(Vaspin) and endothelial cell specific molecule-1(Endocan) in patients with unstable angina combined with hypertension. Methods: Our research included in 4 groups:43 patients with hypertension for HD group,61 patients with unstable angina for UA group,90 patients with unstable angina combined with hypertension for UA with HD group,35 healthy peaple for control group,All patients were diagnosed and treated in our hospital from 2017-02 to 2018-02.Vaspin and Endocan were detected by ELISA. Results: Compared with control group,Vaspin and Endocan level in HD,UA and UA with HD groups were statistically significant difference(P<0.05),and Vaspin level gradually declined while Endocan increased.Pearson correlation analysis showed that the level of Vaspin was negatively correlated with the number of coronary lesions and the Gensini score(P<0.05), while Endocan positively correlated with the number of coronary lesions and the Gensini score(P<0.05),Vaspin and Endocan were negatively correlated(r=-0.715,P<0.05).ROC curve analysis showed that the area under curve of UA with HD and HD groups with Vaspin and Endocan were 0.877、0.850,respectively(P<0.05), and the UA with HD and UA groups were 0.692、0.689,respectively(P<0.05).Conclusion: Vaspin and Endocan were related to the severity of cardiovascular disease and could be used for predicting the early prognosis in unstable angina combined with hypertension.

Key words： Vaspin Endocan Unstable angina Hypertension

基金资助:河北省承德市科学技术研究与发展计划项目,(编号:201801A026)

通讯作者: 侯瑞田

引用本文:

刘秋梅, 金凤表, 张英, 李博, 张爱文, 张志敏, 丁振江, 侯瑞田. 血清Vaspin Endocan在不稳定型心绞痛合并高血压病的表达及其临床意义[J]. 河北医学, 2019, 25(2): 245-249.
LIU Qiumei, JIN Fengbiao, ZHANG Ying, et al. Expression and Clinical Meaning of Serum Endocan and Vaspin Levels in Patients with Unstable Angina Combined with Hypertension. HeBei Med, 2019, 25(2): 245-249.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2019.02.019 或 http://www.hbyxzzs.cn/CN/Y2019/V25/I2/245

[1] Motawi TK, Mahdy SG, Maha M. El-Sawalhi,et al. Serum levels of chemerin, apelin, vaspin, and omentin-1 in obese type 2 diabetic Egyptian patients with coronary artery stenosis[J]. Can Physiol Pharmacol,2017,96: 38~44.
[2] Tariket S, Sut C, Arthaud CA, et al. Modeling the effect of platelet concentrate supernatants on endothelial cells: focus onendocan/ESM-1[J].Transfusion, 2017.
[3] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)[J].Chin Cardiol, 2017, 45(5): 359~376.
[4] Tony Stanton, MBChB, PhD, et al.Hypertension, Left Ventricular Hypertrophy, and Myocardial Ischemia[J]. 2017,29~41.
[5] Wang LQ,Sun LM,Wang YL,et al.The effect of rosuvastain and atorvastain on serum adipokine Vaspin in patients with coronary heart disease[J].Pract Med,2015,31(2):289~293.
[6] Motawi TK, Mahdy SG, Maha M. El-Sawalhi,et al. Serum levels of chemerin, apelin, vaspin, and omentin-1 in obese type 2 diabetic Egyptian patients with coronary artery stenosis[J]. Can Physiol Pharmacol,2017,96: 38~44.
[7] Wei Yang, Yun Li, Tian Tian, et al.Serum vaspin concentration in elderly patients with type 2 diabetes mellitus and macrovascular complications[J].BMC Endocrine Disorders,2017,17(1):67.
[8] Sakamoto Y, Kameshima S, Kakuda C, et al. Visceral adipose tissue-derived serine protease inhibitor prevents the development of monocrotaline-induced pulmonary arterial hypertension in rats[J].Pflugers Arch - Eur Physiol,2017,469:1425~1432.
[9] Kameshima S, Kazama K, Okada M, et al.Eukaryotic elongation factor 2 kinase mediates monocrotaline-induced pulmonary arterial hypertension via reactive oxygen species-dependent vascular remodeling[J].Am Physiol Heart Circ Physiol,2015, 308(10): H1298~H1305.
[10] Icli A, Cure E, Cure MC, et al. Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus.Angiology[J]. Angiology, 2016, 67(8):749~755.
[11] M. Kose, S. Emet, T.S. Akpinar, et al. Serum endocan level and the severity of coronary artery disease: a pilot study[J].Angiology, 2015,66(8):727~731.
[12] Cimen T, Efe TH, Akyel A, et al.Human Endothelial Cell-Specific Molecule-1 (Endocan) and Coronary Artery Disease and Microvascular Angina[J].Coronary Artery Disease, 2016, 67(9): 846~853.
[13] Musialowska D, Zbroch E, Koc-Zorawska E, et al. Endocan Concentration in Patients With Primary Hypertension[J].Angiology, 2017,1:1~7.
[14] Celik T, Balta S, Karaman M, et al. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension:comparative effects of amlodipine and valsartan[J]. Blood Press, 2015, 24(1):55~60.